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The incidence of head and neck cancer continues to rise annually, most 
commonly squamous cell carcinoma (SCCa). Advances in imaging techniques 
have improved diagnostic accuracy with important ramifications for initial staging 
and post-treatment surveillance. FDG-PET/CT and, more recently, FDG-
PET/MRI have revolutionized the staging and surveillance of head & neck SCCa. 
We detail the diagnostic role of FDG-PET/CT and FDG-PET/MRI of SCCa at the 
different head and neck subsites, highlighting their role in identifying the primary 
tumor extent, regional nodal metastases, and distant metastatic disease in the 
pre-treatment and post-treatment setting, as well as implications for staging, 
treatment, and prognosis.  
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Head and neck cancer is the sixth most common malignancy accounting 
for approximately 40,000 patients each year in the United States (US).[1, 2] 
Ninety-five percent of the head and neck cancers are histopathologically 
squamous cell carcinoma (SCCa) and found to arise from the mucosal surface of 
the oral cavity, oropharynx, hypopharynx, larynx, sinonasal cavity, and 
nasopharynx.[1] Locally advanced SCCa occurs in approximately two-thirds of 
patients with or without regional lymph node involvement.[3] Early-stage SCCa 
has a very favorable prognosis while more advanced disease has a poor 
prognosis and worse functional outcome.[4] Prognosis largely depends on the 
tumor type, histological variant, grade, and human papillomavirus (HPV) status. If 
all stages of head and neck cancer are considered, the 5-year survival is 
approximately 40-70%.[1, 5]  
Currently, both CT and MRI are used to assess disease presence, tumor 
burden, and nodal involvement. Compared to CT, MRI offers superior soft tissue 
contrast resolution and demonstrates better sensitivity and specificity for 
differentiating whether a mass has adjacent soft tissue invasion, including 
perineural tumor spread.[7] While CT and MRI have similar success in detecting 
occult nodal metastasis, these modalities nevertheless show poorer sensitivity in 
determining involvement of nonenlarged lymph nodes relative to F18-fluoro-2-
deoxyglucose (FDG) positron emission tomography (PET).[3]  
In the United States, FDG-PET/CT has become commonplace during 
initial staging of head and neck SCCa, as well as during the post-
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operative/treatment follow-up.[1, 5]. More recently, there has been the addition of 
PET/MRI, which combines the excellent soft tissue contrast resolution of MRI 
with the metabolic sensitivity of PET.[7] PET/CT or PET/MRI combines both 
diagnostic and functional imaging to aid in the detection of the primary tumor and 
potential metastatic foci locally and distantly.[8]  
FDG-PET is a critical tool in oncologic imaging due to its ability to 
determine abnormally elevated levels of aerobic glycolysis in cancer cells.[5] The 
degree of FDG uptake in tissue is measured as the Standardized Uptake Value 
(SUV), which is a semi-quantitative value of the normalized concentration of 
radioactivity present within a lesion that is used to determine the glucose 
metabolism of the tumor.  Thus, there is a well-studied association between FDG 
uptake in a tumor and the tumor burden. The SUV and volumetric parameters of 
PET/CT have been found to indirectly measure the expression of various 
markers of tumor aggressiveness. Moreover, multiple studies have shown 
correlation of the SUVmax with tumor stage, size and tumor dedifferentiation.[1] 
Pretherapy biomarkers such as elevated SUVmax, metabolic tumor volume, and 
total lesion glycolysis portends a poor prognosis.[6] 
PET/CT is used to determine the presence of locoregional invasion, lymph 
node involvement and metastatic disease, and is implemented for staging, as 
well as surgical, radiation, and chemotherapy planning. In the post-treatment 
setting, PET/CT is employed to assess therapy response and to identify residual 
or recurrent disease.[1] PET/MRI has the potential to improve diagnostic 
accuracy where soft tissue contrast resolution is limited on CT or where CT 
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yields artifacts.[7] Additionally, given the etiology of most head and neck cancers, 
it is prudent to recognize that patients with head and neck SCCa have a higher 
prevalence of synchronous and metachronous primary tumors for which PET/CT  
and PET/MRI evaluation improves detection. [6] 
Head and neck SCCa has a relatively low rate of distant metastatic 
disease (2-18%); however when it is present, there is a much poorer prognosis. 
The most common locations for metastatic disease from the head and neck are 
the lung followed by liver and bone. PET/CT evaluation for distant metastatic 
disease is important for proper treatment planning as the negative predictive 
value (NPV) for distant metastatic disease on PET/CT is 99%.[5]  
Early stage disease in the head and neck is primarily treated surgically, 
which can result in a significant impact on quality of life due to impaired 
swallowing, speech deficits, and cosmetic deformity.[5] At an advanced stage the 
patient may undergo concurrent platinum-based chemoradiotherapy followed by 
surgery or surgical resection of the primary tumor with neck dissection followed 
by adjuvant chemoradiation. Despite these curative attempts, tumor recurrence 
remains common, and due to extensive posttreatment changes including edema, 
hyperemia, scarring, and loss of fascial planes, identification of recurrence 
remains challenging with imaging.[6] PET/CT is commonly used to assess initial 
treatment response due to the ability to detect viable tissue in the posttreatment 
neck. Despite the aggressive treatment options, many of these cancers 
unfortunately recur at the primary tumor site or locoregionally; therefore, these 
patients require continuous imaging surveillance. Kim et al have shown that PET 
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has a sensitivity of 86-100%, specificity of 43-97%, positive predictive value 
(PPV) of 42-71%, and a NPV of 98-100% in detecting persistent or recurrent 
disease after treatment. The PPV is low because PET/CT has a high false-
positive rate due to post-treatment inflammation.[5] 
Due to the post treatment inflammation, post treatment timing of the 
PET/CT to assess for tumor recurrence is critical. Timing is difficult to optimize, 
as it differs due to the extent of treatment and other patient-intrinsic factors. 
Detection of the earliest possible recurrence is necessary because recurrence 
greatly affects the outcome of salvage surgery.[9] The NPV is lower when the 
PET/CT is performed between 4 and 7 weeks post-treatment, while there is a 
higher NPV when the scan is delayed until 12 weeks after therapy. Goel et al 
determined that when the PET/CT was delayed 12 weeks or more after therapy, 
there was an improved sensitivity of 80% (versus 73%). Thus, the general 
consensus is PET/CT imaging should be delayed at least 12 weeks following 
treatment and this is the recommendation by the National Comprehensive 
Cancer Network (NCCN) clinical practice guidelines for head and neck 
carcinoma.[5,6]  
Subsite-Specific PET/CT and PET/MRI Considerations 
Nasal Cavity/Sinonasal 
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Sinonasal carcinomas are very rare and account for 3% of all head and 
neck cancers.[10] The major risk factors for developing sinonasal carcinomas 
include inhaled wood dust, chrome pigment, leather dust, isopropyl alcohol 
production, nickel, and radium 226 and 228 (and their decay products).[10] 
Exposures to these toxins are known to increase the risk of SCCa by 20 
times.[11] According to the World Health Organization classification, there are 44 
different histologic types of sinonasal malignancies, and the majority of these 
histologic types are of epithelial origin. There are 19 different epithelial 
malignancies, which includes the most common SCCa. Less common types 
include intestinal and non-intestinal type adenocarcinomas, salivary gland type 
carcinomas, and neuroendocrine tumors. SCCa itself accounts for 50-80% of all 
of the sinonasal malignancies and is most commonly found in 50-60 year-old 
males.[11]  
Tumors of the nasal cavity are typically found at an advanced stage in 75-
89% according to Lee et al because most of the symptoms that occur are very 
similar to the symptoms of chronic rhinosinusitis, resulting in delayed diagnosis. 
The prognosis markedly worsens if the maxillary sinus tumor invades posteriorly 
into the pterygomaxillary and infratemporal fossae versus when the tumor is 
confined to the anteroinferior portion of the sinus. Once the tumor invades these 
posterior structures, a simple en bloc surgical resection is difficult. Metastatic 
disease to the lymph nodes with sinonasal carcinomas occurs in approximately 
7-15% according to Lee et al, and distant metastatic disease is quite rare. When
local recurrence occurs after surgery, it most commonly occurs in the posterior 
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aspect of the maxillary sinus, periorbita, and the skull base. The 5-year survival 
rate with sinonasal SCCa is around 50% while the recurrence rate is 
approximately 56%.[12] 
The imaging characteristics of SCC overlap with many other sinonasal 
malignancies, thus making it difficult or impossible to differentiate specific 
pathologies on imaging alone.  On CT, SCCa typically presents as a 
heterogeneous solid mass with areas of central necrosis and irregularity with 
potential osseous destruction. Due to cellularity, a SCCa mass is often T2 
hypointense on MRI, but may show areas of intrinsic T1 hyperintensity related to 
blood products, in addition to variable enhancement. On FDG PET/CT, sinonasal 
SCCa typically shows avid metabolic activity (Figures 1 and 2). However, these 
imaging findings are not specific to SCCa and can be found with other sinonasal 
malignancies, such as the less aggressive sinonasal adenocarcinoma. There are 
some differentiating imaging findings that can aid in suggesting a SCCa over 
adenocarcinoma, for example SCCa more commonly arises in the maxillary 
sinus antrum, enhances less, and have less well-defined margins.[11] 
Sinonasal inverted papilloma (IP) is a common benign tumor of the 
sinonasal cavity and is known to be locally aggressive with a high rate of 
postoperative recurrence. According to Lee et al, IPs account for approximately 
0.5-4% of all sinonasal tumors, and occasionally can harbor SCCa or undergo 
malignant transformation in approximately 9% of cases. Lee et al also stated that 
the 5-year survival rate for an IP is approximately 63% compared to 50% for 
sinonasal SCCa. It is difficult to differentiate a benign IP from an IP harboring 
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SCCa on routine MRI or CT imaging. Additionally, a biopsy sample may not 
identify the presence of SCC residing within the IP. It was initially thought that 
PET/CT may be of benefit in the identification of SCCa in an IP, but this has 
proven unreliable.[13] IPs have been found to have FDG uptake varying from 
minimal to marked (Figure 3). FDG-PET, however, may be useful when 
differentiating sinonasal IP from adjacent postoperative fibrosis and mucosal 
edema in suspected recurrent or residual IP.[14] 
Nasopharynx 
The nasopharynx includes the posterior choana, torus tubarius, 
Eustachian tubes, fossa of Rosenmüller, and the posterior pharyngeal wall. The 
superior-most boundary of the nasopharynx is the skull base and the inferior 
border is the soft palate.[15]  
Nasopharyngeal carcinoma (NPC) is the leading cause of cancer deaths 
amongst the Cantonese population in Southern China and Hong Kong and rare 
in other parts of the world. There are three types of known NPC, including 
keratinzing SCCa (type I), non-keratinizing differentiated carcinoma (type II), and 
non-keratinizing undifferentiated carcinoma (type III). The undifferentiated 
carcinoma subtype is the most common, occurs in endemic areas, accounts for 
93% of all of the NPC cases according to Mohandas et al, and are very 
commonly associated with Ebstein Barr virus infection. Differentiated carcinoma 
of the nasopharynx occurs in non-endemic areas, accounts for as many of 50% 
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of cases, and is associated with smoking and alcohol intake.  SCCa of the 
nasopharynx is the rarest of all of the subtypes and has the worst prognosis. 
Radiation is the primary treatment of choice with localized disease, but 
chemotherapy is added in locally advanced cases.[16] 
The American Joint Committee on Cancer (AJCC) has recently changed 
the T category of NPC. If there is involvement of the bony structures (paranasal 
sinuses, ptygeroid, skull base, vertebrae), the T category is now considered T3. 
Also, if the tumor involves the lateral or medial ptyergoid muscles or prevertebral 
muscles T category is considered T2, while it is considered T4 if there is 
extension of tumor beyond the lateral surface of the ptygeroid musculature or 
involvement of the parotid gland. These changes reflect  a better prognosis if 
there is infiltration of the lateral ptygeroid muscle versus extension lateral to the 
muscle.[17]  
MRI has been found to be an excellent imaging modality due to its 
excellent spatial resolution and soft tissue contrast in managing NPC, whereas, 
CT is more commonly used in initial staging and radiation planning. MRI 
demonstrates superior sensitivity at determining the extent of disease and 
whether there has been spread of the primary tumor into the parapharyngeal 
space, orbit, paranasal sinuses, and/or retropharyngeal adenopathy, which 
impacts staging and treatment planning.[16]  
PET/CT has been found to be a valuable imaging modality in staging 
NPC, although it tends to underestimate tumor volume and extent at the 
nasopharynx, skull base, brain, cavernous sinuses, and orbits when compared to 
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MRI.  Underestimation may be due to overall decreased FDG avidity in early 
disease, overall decreased resolution of PET/CT versus MRI, and high metabolic 
uptake of the adjacent brain, which may obscure adjacent tumor uptake (Figure 
4). Due to the inability of PET/CT to resolve soft tissue details it is difficult to 
differentiate between tumor invasion versus tumor compression of the 
surrounding tissues.[16] However, FDG-PET/CT can detect small NPCs which 
are occult on both MRI and CT.[18] FDG-PET/CT has a sensitivity of 96%, 
specificity of 94%, PPV of 96% and NPV of 94% which is significantly higher than 
CT alone (71%, 76%, 80%, and 67%). PET/CT has been shown to result in 
downstaging of NPC in 17-23% of cases and upstaging in 8-10%.[16] 
The presence of metastatic lymphadenopathy in the setting of NPC is 
associated with a poor prognosis. This is especially true in N3 category disease, 
where there is bulky (conglomerate) lymphadenopathy measuring > 6 cm, or 
lower neck (below the caudal border of the cricoid cartilage) metastatic lymph 
nodes. Also, Ai et al showed that there is a high propensity of NPC nodal disease 
to demonstrate extranodal extension (ENE), thought to occur in in 33.6-39.8% of 
cases. However, in contrast to the significant effect of ENE on locoregional 
control and overall survival for oropharyngeal carcinoma, this is different for NPC 
where patient survival/prognosis is largely dependent on a high total nodal 
volume and nodal necrosis.[19] 
PET/CT has been found to have a high accuracy rate in assessing 
metastatic lymph nodes in NPC. When evaluating lymph nodes with diagnostic 
imaging such as MRI and CT, the assessment depends on morphology, size, 
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and enhancement. This may lead to missed pathological nonenlarged nodes 
harboring microscopic tumor cells PET/CT, on the other hand, has a sensitivity of 
97-100% and a specificity of 73-97% in evaluating such nodal disease in NPC
while MRI sensitivity and specificity is much lower (73-97%), according to 
Mohandas et al. PET/CT has been found to be more accurate with infrahyoid 
neck lymph nodes involvement, while retropharyngeal lymph nodes are more 
difficult to detect likely due to marked uptake from the adjacent NPC. However, 
the addition of intravenous contrast markedly improves retropharyngeal node 
detection.[16]  
PET/CT has a very important role in the detection of distant metastatic 
disease, thus having a direct impact on treatment and prognosis. One study 
found that PET/CT changed the treatment in 33% of patients with NPC, related to 
both detection of nodal disease and metastatic disease not otherwise identified 
on other diagnostic imaging studies.[16] 
PET/CT is the study of choice for post-treatment imaging in determining 
the presence of residual and recurrence of disease and differentiating it from 
post-radiation changes/inflammation (Figure 5). The sensitivity and specificity of 
post-treatment PET/CT in detecting residual/recurrence disease is 95% and 90% 
respectively, according to Mohandas et al. When a NPC is first diagnosed as a 
T4 category, it has been found that PET/CT has a much higher specificity for 
recurrence when compared to MRI (96% versus 63%). The new development of 
PET/MRI has the potential to even be better than PET/CT and MRI alone, 
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PET/MRI can better delineate the detail with intracranial spread, retropharyngeal 
lymphadenopathy, and perineural tumor spread (PTNS).[16] 
Oropharynx 
The oropharynx includes the base of tongue, soft palate/uvula, posterior 
wall of the pharynx, valleculae, palatine/lingual tonsils, and anterior/posterior 
tonsillar pillars.[15]  
Many head and neck SCCa have a high association with alcohol and 
tobacco use. More recently, human papilloma virus (HPV) infection (most 
commonly HPV type 16) has been found to be a major etiology of oropharyngeal 
SCCa, and in the United States, HPV-related SCCa accounts for approximately 
70% prevalence among oropharyngeal HPV. Relative to traditional demographics 
of non-HPV SCCa, HPV SCCa occurs in a younger patient population, most 
commonly white males, and is strongly associated with high risk sexual 
behavior.[20] HPV positive oropharyngeal tumors can be detected via 
immunohistochemistry for p16 kinase inhibitor, which is important for stratifying 
management as these tumors respond better to chemotherapy, radiation, and 
chemoradiation therapies resulting in a better prognosis then HPV negative 
SCCa of the oropharynx. Also, HPV positive tumors tend to need less frequent 
imaging surveillance.[6] Most commonly p16 positive tumors present with 
multiple, bulky, bilateral lymphadenopathy with a much better survival than their 
p16 negative counterparts with the same imaging findings.[17] 
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The presence of nodal disease continues to be an important prognostic 
factor, according to Goel et al, with rates of survival decreasing by 40-50% with 
the presence of metastatic cervical lymph nodes. The major advantage of 
PET/CT is detecting metabolically active lymph nodes which are clinically occult, 
nonenlarged on MRI or CT imaging, and otherwise would have not been 
detected (Figure 6). Even in suspected N0 neck disease, there remains a 20-
30% chance of occult nodal disease; therefore, these patients typically undergo 
an elective neck dissection in order to accurately stage the patient.[6] 
In the posttreatment setting of oral cavity and oropharyngeal cancer, the 
imaging modalities which influence clinical decisions are CT, MRI and PET/CT. 
Additionally, per the NCCN, regular clinical examinations remain imperative in 
post-treatment follow-up.[9] PET/CT is an accurate and sensitive imaging 
modality for post-treatment evaluation of patients with oropharyngeal SCCa over 
CT alone.[20] PET/CT is very important in detecting residual or recurrent 
disease, as early detection of recurrence is extremely important in the potential 
usage of salvage neck surgeries (Figure 6).  
There are persistent challenges that radiologists face when reading 
posttreatment PET/CT studies. First, the optimal time interval for the initial post 
treatment evaluation is 12 weeks. Acquiring PET images prior to 12 weeks can 
result in false negatives and some false positives due to postsurgical fibrosis, 
edema, and inflammation. Moreover, loss of symmetry and normal fascial 
boundaries from treatment changes may obscure tumor recurrence or may make 
identification of recurrent disease more challenging. In order to be the most 
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helpful to the clinician in these cases, the radiologist must have a firm 
understanding of the anatomy and be able to identify potential involved subsites, 
as these areas affect the patient’s treatment. These subsites include the 
posterior oropharyngeal wall, palatine tonsils/tonsillar pillars, base of tongue, and 
the soft palate/uvula.[9] On occasion, the tumor may be masked due to the 
adjacent, normal, physiologic uptake of the pharyngeal lymphoid tissues. Also, 
false-positive results are more likely to occur in locations prone to inflammatory 
processes such as the palatine tonsils and Walderyer ring of lymphoid tissue. 
Most of these difficulties with PET/CT can be overcome with the addition of a 
diagnostic post-contrast CT of the neck.[6, 18] 
Oral Cavity 
The oral cavity includes the hard palate, retromolar trigone, anterior two-
thirds of the tongue, floor of the mouth, maxillary/mandibular alveolar ridges, 
teeth and gingiva, bucca mucosa, and lips. Tumor involvement of these subsites 
can drastically affect the patient’s treatment plan and need to be assessed on 
imaging.[9,15] 
The oral cavity is often difficult to assess on CT due to substantial artifacts 
from dental restorations or appliances and MRI, PET/CT, or PET/MRI may be of 
benefit (Figure 7). PET/CT has been found to more accurately characterize the 
primary tumor.  MRI does not experience the same artifacts as CT; however, MRI 
is more sensitive to patient motion artifacts.[6, 18] Mandibular involvement is 
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extremely important in surgical planning, and the diagnostic CT portion of the 
PET/CT highly aids in the determination of osseous involvement with a high 
sensitivity (83-96%) and variable specificity (53-92%), according to Goel et al. 
Goel et al also determined that PET/CT has a sensitivity of 100% and specificity 
of 85% when it comes to mandibular tumor involvement. Therefore, PET/CT can 
aid in accurate primary tumor staging and help with radiotherapy and surgical 
planning.[6] 
In the recent AJCC Cancer Staging Manual, 8th Edition, the staging of oral 
cavity carcinomas was updated to remove the previously-included extrinsic 
tongue muscles involvement. Although removed due to lack of prognostic value 
of this finding, invasion of the extrinsic tongue muscles remains important for 
surgical planning and reconstruction purposes. The depth of invasion (DOI) of 
the tumor was recently added to the staging criteria; however, this is a pathology 
finding rather than an imaging finding and is believed to be most consistent with 
tumor thickness on imaging. The tumor thickness on imaging includes the 
endophytic and or exophytic components of the tumor, thus tends to over or 
underestimate what the pathologist measures to be the true DOI. PET/CT has 
been found to have high accuracy in the detection of primary tumor (Figure 7), 
however, due to poor spatial resolution there is PET/CT may be lacking in the 
determination of tumor extent into neighboring soft tissues, an area where 
PET/MRI theoretically offers superior advantage.[6, 18] 
In oral cavity SCCa, the presence of lymph node micrometastases remain 
a challenge on imaging. The surgeon often elects to complete a neck dissection 
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in these patients for early oral cavity carcinomas, as it is challenging to reliably 
identify occult lymph node micrometastases, particularly if the interpreting 
radiologist relies too heavily on lymph node size as a screening tool for detecting 
nodal metastases. Nevertheless, Weiss et al. found the presence of occult 
metastatic lymph nodes in stage N0 neck cancer occurs in less than 20% of 
cases, and given this data watchful waiting may be considered. Both MRI and 
PET have been found to have NPVs of greater than 80% for occult metastatic 
nodes.[5] When the clinician has a negative neck physical examination in a 
patient with oral cavity SCCa, PET-CT can aid the other diagnostic imaging in 
determining PET avid, suspicious non-enlarged lymph nodes. This is particularly 
helpful in T1-T3 oral cavity SCCa. (Figure 7).[3] 
Larynx 
The larynx is subdivided into the supraglottic, glottic, and subglottic larynx. 
The supraglottic larynx is the origin site of laryngeal SCCa in approximately 30% 
of cases, which may include involvement of the suprahyoid free portion of the 
epiglottis, the infrahyoid fixed portion of epiglottis (petiole), the aryepiglottic folds, 
arytenoids, false vocal folds, laryngeal ventricle, preepiglottic fat, and paraglottic 
space.[15] The glottic larynx is the site origin of laryngeal SCCa in approximately 
65% of cases, which may involve the true vocal folds, anterior commissure, and 
posterior commissure.[15] The subglottic larynx extends inferiorly below the true 
vocal folds and terminates above the first tracheal ring. It is uncommon for SCCa 
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to primarily originate within the subglottic, although involvement of the subglottic 
larynx is much more commonly seen with transglottic extension of tumor.[15]  
Over the years, due to improved surgical techniques patients have had a 
better quality of life; however, despite this fact, the overall survival has not 
improved greatly due to advanced stage at time diagnosis. Most of the causes of 
death are due to locoregional recurrences and distant metastatic disease. Due to 
post-surgical/treatment changes after surgery, it is challenging to assess for 
locoregional recurrence on MRI and CT due to changes in anatomy, scar/fibrotic 
tissue, and loss of tissue-fat planes. It is, however, extremely important to be 
able to detect recurrences, as salvage treatment is less successful once the 
disease reaches a more advanced stage. PET/CT is highly reliable in the 
diagnosis of recurrent laryngeal malignancy and lymph node disease with a 
sensitivity of 100%, a specificity of 88%, and an accuracy of 93.3%.[21] 
When the tumor invades the preepiglottic fat and the paraglottic space, 
there is an increased risk for nodal metastatic disease due to the rich lymphatics. 
These tumors also tend to have a higher recurrence rate and worse outcome 
when there is invasion of the thyroid/cricoid cartilages and especially when there 
is full thickness cartilage invasion (Figure 8). The role of MRI and PET/MRI in 
assessment of laryngeal SCCa is not as well established but may be considered 
for trouble shooting indeterminate CT findings, including assessment of cartilage 
invasion and paraglottic extension of laryngeal tumor. Although pretreatment 
PET/CT is excellent as a baseline study, subsequent PET/CTs without contrast 
yields no more information than MRI and CT.[18]  
Downloaded for Anonymous User (n/a) at Indiana University Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on July 22, 2019.













The hypopharynx includes the posterior cricoid pharyngeal mucosa, 
posterior pharyngeal wall, and pyriform sinuses. The superior-most aspect of the 
hyopharynx is at the level of the hyoid bone at the pyriform aperture and the 
inferior-most aspect of the hypopharynx is the lower border of the cricoid 
cartilage.[15] 
SCCa of the hyopharynx is typically diagnosed at an advanced stage and 
therefore, tends to have a poor prognosis, and more than 75% of patients are a 
stage III or IV at the time of initial diagnosis, according to Joo et al. Joo et al, also 
found that nodal disease is typically present in 60-80% of patients at the time of 
diagnosis; therefore, it is ideal to have an imaging modality, such as PET/CT or 
PET/MRI, that will assess local and distant disease. Hypopharyngeal carcinoma 
has a high propensity of involving the local lymph nodes, thus making nodal 
staging crucial in the determination of tumor stage (Figure 9). Currently, the main 
imaging modalities consist of CT, MRI, and PET-CT with increased usage of CT 
and MRI as PET-CT often has erroneous uptake from movement during the 
exam.[22]  
Lymph nodes 
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The presence of metastatic lymph nodes in head and neck SCCa is one of 
the most important factors in predicting patient prognosis; therefore, the patient’s 
otolaryngologist or oncologist must also consider lymph node treatment even if 
metastatic disease is not evident clinically. The presence and extent of lymph 
node disease also helps the surgeon plan for the type of neck dissection or for 
the radiation oncologist to plan the radiation fields. This preoperative surgical 
planning helps decrease duration of the operation and ensures sufficient 
coverage of involved lymphatics.[3]  
In order to identify an abnormal lymph node, the lymph node size and the 
morphologic characteristics must be assessed on imaging. On non-PET imaging, 
a rounded shape, loss of normal fatty hilum, focal cortical thickening, focal nodal 
inhomogeneity, and cystic change (necrosis) are abnormal and suspicious for 
nodal metastases regardless of lymph node size.[17] ENE also significantly 
increases the likelihood for locoregional recurrence and distant metastatic 
disease resulting in a worse prognosis.[3, 22] The presence of ENE, however, is 
not included in the staging of HPV positive SCCa of the oropharynx as it has 
been found to not have a significant impact on prognosis.[17] The main imaging 
modalities for assessment of the presence of ENE are CT and MRI; however, 
surgical removal and pathological assessment remain the most reliable.[22] On 
imaging, ENE can be suggested when there is clear infiltration of perinodal tumor 
beyond the lymph node into the surrounding soft tissues.[17] 
Even though MRI is very often helpful in head and neck SCCa, it has been 
found to have a slightly disappointing sensitivity and specificity when it comes to 
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detecting metastatic nonenlarged lymph nodes. The detection of nodal disease 
on imaging largely depends on abnormal morphologic imaging criteria.[5, 7] 
Contrast-enhanced MRI has been found to have a sensitivity of 72% and a 
specificity of 88% in the detection of metastatic lymph nodes.[23] 
PET/CT, on the other hand, has superior sensitivity in the detection of 
nodal disease when compared to PET, CT or MRI alone (Figure 10). The 
sensitivity of PET/CT is 92-100% with a mixed specificity of 77-93% in the 
detection of metastatic lymph nodes.[5] It has also been found that PET/CT 
yields a very high NPV (94.5-96%) in the surveillance of head and neck SCCa.[1-
3, 8] Occult metastatic cervical lymph nodes have a 71-72% increased detection 
rate with the addition of PET/CT.[3] 
The detection of nodal disease on PET/CT depends on technical factors, 
including the uptake time after radiotracer injection and the study duration for the 
dedicated neck portion of the PET/CT, as well as the burden of metastatic tumor 
within an involved lymph node and the presence or absence of nodal necrosis, 
which can result in false negative PET findings. Yamamoto et al. found that 8 
minute imaging acquisition for the dedicated neck portion of the PET/CT yielded 
higher quality images rather than the typical 2-minute time frame. Additionally, 
with a longer imaging delay there is increased ability to detect small FDG positive 
lymph nodes. PET and MRI together yield a sensitivity of 85% and specificity of 
92%, which is not much different than the individual studies.[5] Specific to 
PET/CT, Keski-Santti et al. report a 3-month post-treatment sensitivity of 59%, 
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specificity of 94%, PPV of 71%, and the NPV of 93% for the detection of 
metastatic lymph nodes.[5] 
Perineural Spread 
PNTS consists of tumor spreading along named nerves away from the 
primary tumor site, which is associated with a poorer clinical prognosis.  Despite 
significant extension along nerves away from the primary site, the patient may be 
asymptomatic and PNTS is difficult to detect at the time of surgery. Traditionally, 
study of choice for PNTS detection is MRI due to high soft tissue contrast 
resolution; however, coupling the superior tissue contrast resolution of MRI with 
the metabolic activity of PET on hybrid PET/MRI systems may yield improved 
detection of PNTS (Figure 11).[18] PNTS is more difficult to identify on CT, but 
may on occasion be detected on PET/CT, manifesting as abnormal curvilinear 
hypermetabolic activity along the affected nerves.  
Skin Cancers 
Nonmelanoma skin cancer has consistently been on the rise with the 
second most common nonmelanoma skin cancer being SCCa.[24] SCCa 
accounts for 20% of all non-melanoma skin cancers and most commonly affects 
Caucasians.[25] More than half of these cutaneous SCCa arise from the head 
and neck. The current staging for nonmelanoma skin cancer includes the tumor 
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size and thickness, level of invasion (beyond the dermis), nodal status, and 
distant metastatic disease.  
Currently, treatment in patients with nodal disease, but without distant 
metastatic disease consists of surgical resection of the primary tumor, neck 
dissection for cervical lymph node involvement, followed by regional post-
operative radiation.[24, 26] SCCa involving the scalp, ear, and lip has been found 
to have a higher recurrence rate and are more likely to have nodal metastasis 
(Figure 12). It is critical to remember that intraparotid lymph nodes represent the 
first order nodal drainage basin for skin of the ear, portions of the scalp, and 
portions of the face. Other risk factors for nodal metastatic disease include prior 
radiotherapy and a large primary tumor. Skin SCCa demonstrates a high 
propensity of having perineural invasion, which is a strong predictor of loco-
regional recurrence.[26] According to Supriya et al, approximately 5% of SCCa 
skin cancers metastasize to the regional lymph nodes; however, in more 
aggressive skin cancers, this may increase to 10-20%.  Prior to surgical 
resection, the evaluation for the presence of lymph node metastasis is mandatory 
due to its associated poor prognosis and an approximate 40% survival at 5 
years. Distant metastatic disease usually occurs in the setting of patients with 
regional lymph node disease, and these patients rarely survive beyond 2 years 
despite aggressive treatment.[26] 
Patients with cutaneous SCCa have been staged utilizing CT or MRI; 
however, with the greater availability of PET-CT, its use in staging has 
increased.[26] PET-CT is well documented in the evaluation of primary SCCa 
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and staging in the head and neck; however, it is less well documented when it 
comes to cutaneous SCCa. It has been found the PET/CT has a high sensitivity 
of locating primary cutaneous SCCa (83.3%).[27] Despite the benefits of PET-CT 
with melanoma, the usage of PET-CT with cutaneous SCCa does not yield the 
same benefits. PET-CT in this clinical scenario has not been found to offer 
additional benefit over conventional CT and MRI imaging when staging the 
primary malignancy. Also, no change in management has been found with the 
addition of PET-CT.[26] 
Conclusion 
SCCa of the head and neck continues to be on the rise in the US. It is 
imperative at diagnosis to know the full extent of the primary tumor, locoregional 
lymph node involvement, and presence of distant metastatic disease; these 
findings have a direct impact on treatment and prognosis and are readily 
assessed with PET/CT or P T/MRI. Pre- and post-treatment PET imaging has 
also become a well-documented method for initial staging and post-treatment 
surveillance in patients with head and neck SCCa, although in some sites in the 
neck it has a higher benefit. Additionally, PET/CT and potentially PET/MRI are 
very helpful in identifying micrometastatic disease in nonenlarged lymph nodes 
when compared to CT and MRI alone.  
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Figure 1. 72-year-old woodworker with T3N2cM0 high grade squamous cell 
carcinoma of the right nasal cavity. Axial CECT (A) shows a soft tissue mass 
(white arrows) centered within the right nasal cavity with extension into the 
superior right maxillary sinus (white arrowhead). Axial T1WI C+ FS MRI (B) 
demonstrates heterogeneous enhancement of the mass (white arrows), which 
enhances much less avidly than the normal sinonasal mucosa (white 
arrowhead). On axial T2WI FS MRI (C) and axial ADC map (D), the mass is 
hypointense (white arrows), indicative of a high cellularity tumor. Axial 18F-FDG 
PET/CT (E) shows markedly high FDG avidity of the right nasal cavity mass 
(black arrows). 
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Figure 2. 85-year-old man with a pT4b nonkeratinizing, moderately differentiated 
squamous cell carcinoma of the left maxillary sinus. Axial T2WI FS MRI (A) 
shows a hypointense mass along the posterior wall of the left maxillary sinus 
(white arrow) with extension into the left pterygopalatine fossa (white arrowhead). 
Axial T1WI C+ FS MR (B) shows a homogeneously enhancing mass (black 
arrow), which enhances less avidly than the adjacent, thickened sinonasal 
mucosa (black arrowhead). Axial ADC map (C) shows the mass to be mildly 
hypointense (white arrow), which suggests a mildly hypercellular mass. 
Pretreatment axial 18F-FDG PET/CT (D) shows the mass to be mildly FDG avid 
(black arrow), as well as delineates the extent of the tumor relative to the 
adjacent non-FDG avid sinus mucosal disease (black arrowhead). Post-
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treatment axial 18F-FDG PET/CT (E) shows no residual/recurrent 
hypermetabolic tumor in the maxillary sinus (black arrow). 
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Figure 3. 31-year-old man with recurrent inverted papilloma status post multiple 
prior resections. Coronal bone NECT (A) shows lobular left nasal soft tissue 
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thickening (white arrow) with associated osseous remodeling and rarefaction 
(white arrowheads). Coronal T1WI C+ (B) shows a corresponding lobular 
enhancing mass (white arrow) extending into the postoperative ethmoid air cells 
with opacification of the left frontal sinus (black arrow) due to obstruction at the 
frontal recess. Axial T2WI FS MRI (C) shows the mass to be markedly 
hypointense (white arrow), concerning for a high cellularity tumor. Coronal 18F-
FDG PET/CT (D) shows the mass to be mildly FDG avid (black arrow) relative to 
the surrounding sinonasal mucosa, but less FDG avid than the nearby brain 
parenchyma (black arrowhead). The FDG avidity of the mass was concerning for 
an occult squamous cell carcinoma harbored by the recurrent inverted papilloma; 
however, at resection no malignancy was found. 
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Figure 4. 72-year-old man with poorly differentiated nonkeratinizing squamous 
cell carcinoma of the nasopharynx (HPV-related). Axial temporal bone NECT (A) 
shows osseous destruction along the left skull base (white arrows). Axial T1WI 
C+ FS MRI (B) demonstrates a left nasopharyngeal mass (black arrow) with 
invasion of the left prevertebral soft tissues (black arrowhead) and extension 
along the skull base. Coronal T1WI C+ FS MRI (C) better delineates the skull 
base and intracranial extension (black arrowhead) of the left nasopharyngeal 
mass (black arrow). Axial 18F-FDG PET/CT (D) shows the left nasopharyngeal 
mass to be markedly FDG avid (black arrow). Coronal 18F-FDG PET/CT (E) 
shows the intracranial extension (black arrowhead) of the left nasopharyngeal 
mass (black arrow), but is markedly limited in differentiating FDG avid tumor from 
normal FDG avidity in the brain. 
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Figure 5. 65-year-old man with moderately to poorly differentiated 
nonkeratinizing squamous cell carcinoma of the left nasopharynx (HPV related). 
Axial CECT (A) shows a left nasopharyngeal mass (white arrow) with abnormal 
soft tissue thickening extending posterolaterally (white arrowhead). Pretreatment 
axial 18F-FDG PET/CT shows corresponding FDG avidity in the pharyngeal 
recess of the left nasopharynx (black arrow), as well as FDG avid tumor 
extending posteromedial toward the left carotid space (black arrowhead). 6-
month post-treatment axial 18F-FDG PET/CT (C) shows no significant FDG 
uptake at the primary mucosal site (black arrow), as well as no significant FDG 
uptake corresponding to persistent mild left lateral retropharyngeal soft tissue 
(black arrowhead), consistent with treated disease. 
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Figure 6. 58-year-old man with T4aN2cM0 poorly differentiated invasive 
squamous cell carcinoma of the right palatine tonsil. Axial CECT (A) shows an 
invasive right palatine tonsil mass (white arrow) with extension to the retromolar 
trigone (black arrow), as well as a morphologically suspicious, rounded right leel 
IIA lymph node (white arrowhead). Coronal CECT (B) shows the lateral extension 
of the mass to the right retromolar trigone (white arrow), as well as extension 
along the right maxillary alveolus (black arrow). Coronal bone kernel 
reconstruction (C) shows cortical erosion along the maxillary alveolus (black 
arrow). Axial F18-FDG PET/CT (D) shows the marked FDG avidity of the right 
tonsilar mass (black arrow), as well as the deep invasion of FDG avid tumor to 
the retromolar trigone (black arrowhead). Additional axial F18-FDG PET/CT (E) 
shows extension of FDG avid tumor along the right glossotonsilar sulcus (black 
arrow), as well as confirms previously suspected metastatic adenopathy at the 
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level IIA station (black arrowhead). 5-month post-treatment axial F18-FDG 
PET/CT (F) shows persistent moderately elevated FDG avidity in the region of 
previously treated mass (black arrows), which was biopsy confirmed as residual 
or recurrent disease. The patient continued chemoradiation, and 12-month post-
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Figure 7. 80-year-old woman with poorly differentiated squamous cell carcinoma 
of the oral cavity. Axial CECT through the oral cavity (A) shows marked streak 
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artifact from the patient’s numerous dental restorations, which obscures the oral 
cavity. Axial F18-FDG PET/CT shows a large oral cavity mass that extends along 
both the lingual (black arrow) and buccal (black arrowhead) surfaces. Additional 
axial F18-FDG PET/CT shows a nonenlarged, but FDG avid left level IIA lymph 
node (white arrow) representing nodal metastasis. 
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Figure 8. 50-year-old man with T2N0M0 poorly-differentiated squamous cell 
carcinoma of the supraglottic and glottic larynx. Axial CECT (A) shows an 
irregular-shaped mass centered in the right true vocal fold (white arrows), which 
extends to the anterior commissure (white arrowhead). The patient was lost to 
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follow-up and returned 6 months later, when a repeat axial CECT (B) shows 
marked interval enlargement of the laryngeal mass (white arrows), which now 
crosses midline and demonstrates extralaryngeal extension through the thyroid 
cartilage and into the overlying strap musculature (white arrowhead). A follow-up 
axial 18F-FDG PET/CT (C) performed 6 months later shows marked, diffuse 
FDG avidity throughout the glottic larynx (black arrows) corresponding to the 
enlarging mass. Lack of FDG uptake centrally (black arrowhead) is due to 
necrosis of the tumor centrally. 
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Figure 9. 65-year-old man with T2N2bM0 moderately differentiated, HPV 
negative squamous cell carcinoma of the right hypopharynx. Axial CECT (A) 
shows an avidly enhancing mass centered in the right pyriform sinus (white 
arrow). Additional axial CECT (B) shows enlarged right level III lymph nodes 
(white arrows), which are highly concerning for nodal metastases. Pretreatment 
axial F18-FDG PET/CT (C) shows marked FDG avidity corresponding to the 
hypopharyngeal mass (black arrow), as well as FDG avidity within a right neck 
nodal metastasis (black arrowhead). The patient underwent chemoradiation with 
resolution of the primary hypopharyngeal malignancy (not shown), but post-
treatment axial F18-FDG PET/CT (D) showed persistent FDG avidity in right 
neck metastatic adenopathy (black arrow) due to residual disease. 
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Figure 10. 38-year-old man with pT2pN2bM0 invasive squamous cell carcinoma 
of the left palatine tonsil, HPV 16/18 positive. Axial CECT (A) shows marked 
asymmetric enlargement of the left palatine tonsil (white arrow) with associated 
effacement of the left parapharyngeal fat (white arrowhead). Additional axial 
Downloaded for Anonymous User (n/a) at Indiana University Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on July 22, 2019.












CECT (B) identifies a non-enlarged left level IIB lymph node (white arrow), which 
is suspicious based upon its morphology with lack of fatty hilum and rounded 
contour. Axial T2WI FS (C) identifies the same morphologically suspicious lymph 
node (white arrow), which is mildly heterogeneous in signal intensity, but not 
conclusive for nodal metastasis on the conventional CT and MR imaging. 
Pretreatment axial F18-FDG PET/CT (D) shows increased FDG avidity in the 
same left level II lymph node (black arrow), increasing confidence in predicting 
metastatic adenopathy, which was confirmed at time of neck dissection. 
  
Downloaded for Anonymous User (n/a) at Indiana University Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on July 22, 2019.












Downloaded for Anonymous User (n/a) at Indiana University Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on July 22, 2019.













Figure 11. 61-year-old man with aggressive left maxillary sinus squamous cell 
carcinoma. Axial T1WI C+ FS MRI (A) shows an enhancing mass centered within 
the left maxillary sinus (white arrow) with tumor extension into the left 
infrazygomatic masticator space (black arrow), retromaxillary fat, and 
pterygopalatine fossa. Note addititional perineural tumor spread along CNV2 in 
the foramen rotundum (white arrowhead) with extension to the anterior 
cavernous sinus (black arrowhead). Axial 18F-FDG PET/MR with fused T1WI (B) 
confirms hypermetabolic tumor in these locations (black arrows), as well as (C) 
delineates perineural tumor spread along CNV2 in the foramen rotundum (black 
arrowhead) and invading the inferior orbital fissure (white arrowhead). 
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Figure 12. 75-year-old male with invasive squamous cell carcinoma of the left 
temporal scalp. Axial NECT (A) shows an invasive left preauricular skin cancer 
(white arrow) with deep invasion into the subcutaneous tissues. Axial 18F-FDG 
PET/CT (B) demonstrates marked FDG avidity within the primary tumor (black 
arrow), which was subsquently resected. A follow up axial CECT performed 3 
years later (C) shows a highly concerning, enlarged left level V lymph node 
(white arrow) with rounded morphology and loss of fatty hilum. Axial T1WI C+ FS 
(D) shows this lymph node to have concerning heterogeneous
hyperenhancement (white arrow), including shaggy enhancement at its margin 
(white arrowhead), concerning for extranodal extension (ENE) of tumor. Axial 
18F-FDG PET/MRI with fused T1WI C+ FS (E) shows associated 
hypermetabolism within the level V node (black arrow), as well as mildly 
increased FDG uptake in the adjacent enhancing soft tissue (black arrowhead), 
which remains concerning for ENE. 
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